Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The 403 error and study-record navigation have disappeared, along with an NIH transition announcement. The site frame and footer remain, but the main page content is not visible.
    Difference
    3%
    Check dated 2026-11-07T11:57:29.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T12:37:44.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website transition updates and says the agency is using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-24T12:29:21.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T12:54:15.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1, while the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T13:15:17.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record NCT04505826, replacing the previous content visible to users. This indicates an access restriction or server-side issue that prevents loading the study details.
    Difference
    18%
    Check dated 2026-09-19T18:26:43.000Z thumbnail image

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.